22:24 , Jan 5, 2018 |  BioCentury  |  Finance

Scholar goes to the clinic

While Scholar Rock LLC’s series C round will bring the biotech’s lead program into the clinic, investors also want continued investment in the company’s growth factor modulation platform to maximize its value. On Jan. 3, Scholar...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Ember Therapeutics, Knight Therapeutics deal

Ember granted Knight exclusive rights to commercialize Ember’s bone morphogenetic protein 7 ( BMP7; OP-1) pipeline in Canada, Israel, Russia and sub-Saharan Africa. The lead product has completed a Phase IIa trial to treat...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Ember Therapeutics, Mariel deal

Obesity and diabetes company Ember and Mariel, which is developing compounds targeting bone morphogenetic protein 7 ( BMP7; OP-1), will merge and form Ember Therapeutics Inc. The companies did not disclose financial terms and...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Olympus Corp. musculoskeletal news

Olympus said it will discontinue operations for its U.S. biotechnology division, Olympus Biotech Corp., which includes a facility in Hopkinton, Mass. Olympus said it made the decision for financial reasons. Olympus Biotech will discontinue...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

NeoStem preclinical data

In severe combined immunodeficiency disease (SCID) mice with surgically-induced cranial defects, G-CSF mobilized VSELs isolated from the blood of healthy human donors and transplanted into the defects using collagen sponge scaffolds significantly increased tissue mineral...
07:00 , Oct 11, 2012 |  BC Innovations  |  Cover Story

Ember: warming up to brown fat

A team led by Boston-area researchers has shown that inhibiting a cation channel dubbed TRPV4 induced white fat cells to behave like brown fat, thereby protecting mice from diet-induced obesity and insulin resistance.1Ember Therapeutics Inc....
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Sheep model for load-bearing long bone defects Aged sheep with defects in their long bones could be useful for...
07:00 , May 31, 2012 |  BC Innovations  |  Targets & Mechanisms

Going to BAT

Two teams are reporting new targets for inducing the conversion of white fat to a brown-like phenotype, or boosting the activity of existing brown fat, that could help treat obesity and related metabolic diseases. A...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Ember Therapeutics, Joslin Diabetes Center deal

The center granted Ember Therapeutics exclusive, worldwide rights to IP covering bone morphogenetic protein 7 ( BMP7; OP-1). The company said BMP7 has been shown to play a role in the regulation of brown...
00:34 , Mar 29, 2012 |  BC Extra  |  Company News

Ember in-licenses BMP7 IP from diabetes center

The Joslin Diabetes Center granted obesity and diabetes company Ember Therapeutics Inc. (Boston, Mass.) exclusive, worldwide rights to IP covering bone morphogenetic protein 7 ( BMP7; OP-1). The company said BMP7 has been shown to...